VELTASSA Drug Patent Profile

Which patents cover Veltassa, and when can generic versions of Veltassa launch?

Veltassa is a drug marketed by Vifor Pharma and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and six patent family members in twenty-seven countries.

The generic ingredient in VELTASSA is patiromer sorbitex calcium. One supplier is listed for this compound. Additional details are available on the patiromer sorbitex calcium profile page.

DrugPatentWatch^® Generic Entry Outlook for Veltassa

Veltassa was eligible for patent challenges on October 21, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 29, 2030. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VELTASSA

International Patents:	206
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VELTASSA

Paragraph IV (Patent) Challenges for VELTASSA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VELTASSA	for Oral Suspension	patiromer sorbitex calcium	8.4 g, 16.8 g and 25.2 g	205739	2	2019-10-21

US Patents and Regulatory Information for VELTASSA

VELTASSA is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,337,824.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-003	Oct 21, 2015		DISCN	Yes	No
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-003	Oct 21, 2015		DISCN	Yes	No	8,216,560
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-003	Oct 21, 2015		DISCN	Yes	No	11,123,363
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-004	Oct 2, 2023		RX	Yes	No	8,216,560
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-002	Oct 21, 2015		RX	Yes	Yes	9,492,476
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-002	Oct 21, 2015		RX	Yes	Yes

International Patents for VELTASSA

When does loss-of-exclusivity occur for VELTASSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Finland

Germany

Hong Kong

Hungary

Japan

Lithuania

Luxembourg

Mexico

Netherlands

Norway

Poland

Portugal

San Marino

Slovenia

South Korea

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VELTASSA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	101269766
South Korea	20060135044	ION BINDING POLYMERS AND USES THEREOF
United Kingdom	2475657
South Korea	101228233
China	102202670
South Korea	102300471

Supplementary Protection Certificates for VELTASSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1732523	132018000000061	Italy		PRODUCT NAME: PATIROMER E QUALSIASI SUO SALE O DERIVATO(VELTASSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1179, 20170721
1732523	300925	Netherlands		PRODUCT NAME: PATIROMER EN ALLE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/17/1179/001-009 20170721
2957286	C 2019 004	Romania		PRODUCT NAME: PATIROMER SORBITEX SARE DE CALCIU; NATIONAL AUTHORISATION NUMBER: EU/1/17/1179/001-009; DATE OF NATIONAL AUTHORISATION: 20170719; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1179/001-009; DATE OF FIRST AUTHORISATION IN EEA: 20170719
1732523	300924	Netherlands		PRODUCT NAME: PATIROMER EN ALLE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/17/1179/001-009 20170721
2957286	LUC00094	Luxembourg		PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721
1732523	2018C/004	Belgium		PRODUCT NAME: PATIROMER OF EENDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721

Veltassa: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Veltassa (patiromer) is a potassium binder approved for treating hyperkalemia. Its market position is defined by limited direct competition and a growing patient population due to factors like chronic kidney disease (CKD) and heart failure (HF) prevalence, and increasing use of renin-angiotensin-aldosterone system (RAAS) inhibitors. However, uptake has been moderate, influenced by patient adherence challenges, physician prescribing inertia, and reimbursement landscape.

What is the Market Opportunity for Veltassa?

The global market for hyperkalemia treatments is expanding, driven by the increasing incidence of CKD and HF, conditions that predispose patients to elevated potassium levels. Furthermore, the therapeutic landscape for CKD and HF increasingly relies on RAAS inhibitors, which, while effective, frequently lead to hyperkalemia as a side effect. This creates a sustained demand for effective potassium binders.

Prevalence of Hyperkalemia and Related Conditions

• Chronic Kidney Disease (CKD): Approximately 37 million adults in the United States have CKD. A significant percentage of these individuals, particularly those in later stages, experience hyperkalemia. Globally, CKD affects an estimated 10% of the population, with higher rates in aging demographics and those with diabetes and hypertension. [1]
• Heart Failure (HF): Over 6 million adults in the U.S. have HF. Hyperkalemia is a common complication in HF patients, often exacerbated by diuretic use and RAAS inhibitor therapy. [2]
• RAAS Inhibitor Use: Drugs like ACE inhibitors (e.g., enalapril), ARBs (e.g., losartan), and MRAs (e.g., spironolactone) are cornerstone therapies for HF and CKD. Their use is projected to increase, directly correlating with the potential for RAAS-inhibitor-induced hyperkalemia.

Market Size and Growth Projections

While specific figures for the hyperkalemia treatment market are proprietary, industry reports indicate a compound annual growth rate (CAGR) in the mid-single digits for potassium binders. Factors contributing to this growth include:

• Increased Diagnosis: Greater awareness and diagnostic capabilities for hyperkalemia.
• Aggressive RAAS Inhibition: Prescribing RAAS inhibitors more broadly to manage HF and CKD, leading to more frequent hyperkalemia.
• Aging Population: Older individuals are at higher risk for both CKD and HF.

The addressable market is substantial, encompassing a significant portion of the CKD and HF patient populations who are at risk or actively experiencing hyperkalemia.

How Does Veltassa Function and What is Its Clinical Profile?

Veltassa (patiromer) is an orally administered, non-absorbed polymer that binds to potassium in the gastrointestinal tract, preventing its absorption and facilitating its excretion in the feces. This mechanism of action allows for sustained control of serum potassium levels.

Mechanism of Action

• Patiromer is a poly(sodium carboxylate-co-divinylbenzene).
• It has a high affinity for potassium ions (K+) and binds to them in the lumen of the colon.
• The bound potassium is then eliminated in the stool.
• Patiromer does not significantly affect the absorption of other electrolytes or medications. [3]

Clinical Efficacy and Safety

Veltassa has demonstrated efficacy in reducing and maintaining serum potassium levels within the target range in patients with hyperkalemia, particularly those treated with RAAS inhibitors.

• Efficacy: Clinical trials have shown that Veltassa can lower serum potassium levels by an average of 0.5 to 1.0 mEq/L within weeks of initiation. Sustained reduction in hyperkalemia events was observed. [4] For example, in the OPAL-HK study, patiromer achieved the primary endpoint of mean change in serum potassium from baseline at week 4 (P<0.001) and demonstrated sustained control over 52 weeks. [5]
• Safety Profile: The most common adverse events reported in clinical trials include mild to moderate gastrointestinal disturbances such as constipation, diarrhea, nausea, and abdominal discomfort. These are generally manageable and often transient. [3] Serious adverse events are rare and not typically attributed to the drug's mechanism.

Dosing and Administration

Veltassa is available as a powder for oral suspension or in tablet form. Dosing is individualized and typically initiated at 8.4 grams once daily, with titration to achieve target serum potassium levels. The maximum recommended daily dose is 25.2 grams. [3] The need for flexibility in dosing and administration is crucial for patient adherence.

What is the Competitive Landscape for Veltassa?

The competitive landscape for potassium binders is evolving, with Veltassa facing competition from established treatments and newer entrants.

Key Competitors

• Sodium Polystyrene Sulfonate (SPS) - Kayexalate/Kionex: This is the oldest potassium binder.
  • Mechanism: Ion-exchange resin that binds potassium in exchange for sodium.
  • Limitations: Efficacy can be variable, potential for significant sodium load leading to fluid retention, risk of intestinal necrosis, and poor palatability. [6]
  • Market Position: Historically dominant, but its use is declining due to safety concerns and efficacy limitations compared to newer agents.
• Patiromer (Veltassa) - Tricida/Sanofi:
  • Mechanism: Binds potassium in exchange for calcium.
  • Advantages: Generally well-tolerated, less risk of sodium load, and demonstrated sustained efficacy.
  • Market Position: A leading agent in the new generation of potassium binders.
• Sodium Zirconium Cyclosilicate (SZC) - Lokelma/AstraZeneca:
  • Mechanism: Binds potassium and ammonium in exchange for sodium and hydrogen.
  • Advantages: Rapid onset of action, demonstrated efficacy in reducing potassium levels, and generally well-tolerated. [7]
  • Market Position: A direct competitor to Veltassa, with a similar patient profile and benefits.

Competitive Differentiation and Challenges

Veltassa's differentiation lies in its established safety profile and ability to provide sustained potassium control, particularly in the context of chronic RAAS inhibitor therapy. However, it faces challenges:

• Lokelma's Onset: Lokelma has shown a faster onset of action in some studies, which may be preferred in acute hyperkalemic crises.
• Adherence: Like all oral medications for chronic conditions, patient adherence to Veltassa can be a barrier to optimal outcomes. Dosing frequency and the need for mixing the powder can impact adherence.
• Cost: Newer agents are generally more expensive than generic SPS, influencing prescribing decisions and reimbursement.
• Physician Prescribing Habits: Inertia in switching from established or familiar treatments (like SPS or even proactive management without binders) can slow adoption.

What are the Key Factors Influencing Veltassa's Commercial Success?

The commercial trajectory of Veltassa is contingent upon several factors, including market access, physician adoption, and patient adherence.

Market Access and Reimbursement

• Payer Coverage: Broad market access through commercial insurance and Medicare/Medicaid is critical. Reimbursement policies, prior authorization requirements, and step-therapy protocols can significantly influence prescribing patterns.
• Pricing Strategy: The price of Veltassa relative to competitors and the perceived value proposition (i.e., ability to stay on RAAS inhibitors) will determine its market share.
• Value-Based Care: Demonstrating that Veltassa reduces hospitalizations or emergency room visits related to hyperkalemia can support its value proposition to payers.

Physician Adoption and Prescribing Trends

• Physician Education: Ongoing education for cardiologists, nephrologists, and primary care physicians on Veltassa's benefits, appropriate patient selection, and dosing strategies is essential.
• Clinical Trial Data Dissemination: Publication and presentation of robust clinical trial data that highlight Veltassa's efficacy and safety are paramount.
• Real-World Evidence: Generating and disseminating real-world evidence demonstrating Veltassa's effectiveness and impact on patient outcomes in routine clinical practice can bolster physician confidence.
• Competition: The presence of Lokelma and the continued, albeit reduced, use of SPS necessitate a clear articulation of Veltassa's unique selling points.

Patient Adherence and Education

• Patient Support Programs: Programs that assist patients with medication adherence, provide education on the condition and treatment, and help navigate insurance challenges are vital.
• Formulation: The availability of both powder and tablet formulations aims to address some patient preferences, but ongoing research into more convenient delivery methods could further improve adherence.
• Understanding of Risk: Patients need to understand the risks associated with untreated hyperkalemia and the benefits of consistent medication use to remain on guideline-directed medical therapy.

What is the Financial Outlook and Investment Rationale for Veltassa?

Analyzing Veltassa’s financial outlook requires an assessment of its revenue potential, cost structure, and the overall health of its parent company or the investing entity.

Revenue Streams and Growth Drivers

• Prescription Volume: Growth is directly tied to increasing diagnosis of hyperkalemia, broader use of RAAS inhibitors, and market share gains against competitors.
• Geographic Expansion: Launch and uptake in international markets beyond the initial launch countries (e.g., US, EU) represent significant revenue expansion opportunities.
• Label Expansion/New Indications: While currently focused on hyperkalemia, any future exploration of other therapeutic areas for patiromer could unlock new revenue streams, though this is speculative.

Cost Structure and Profitability

• Manufacturing Costs: The cost of goods sold (COGS) for Veltassa production is a key determinant of gross margins.
• Sales and Marketing Expenses: Significant investment is required for sales force deployment, physician marketing, and patient education campaigns.
• Research and Development (R&D): Ongoing R&D for potential label expansions, improved formulations, or post-market studies adds to the cost base.

Investment Considerations

• Market Share Capture: The ability of Veltassa to capture and maintain significant market share within the growing hyperkalemia market is the primary driver of investment potential.
• Competitive Positioning: Its ability to compete effectively against Lokelma and differentiate from legacy treatments will dictate long-term success.
• Pipeline Strength of Parent Company: If Veltassa is part of a larger pharmaceutical company's portfolio, its performance will be viewed in the context of the company's overall pipeline and financial health.
• Patent Expiry: Understanding the patent landscape and projected patent expiry dates for Veltassa is crucial for long-term investment viability. Generic competition emerging after patent expiry can significantly erode market share and profitability.

Key Takeaways

Veltassa operates in a growing market driven by the prevalence of CKD, HF, and RAAS inhibitor use, creating a consistent demand for potassium binders. Its efficacy and safety profile offer a competitive advantage, particularly against older treatments. However, market penetration is influenced by patient adherence challenges and competitive pressures from newer agents like Lokelma. Success hinges on securing favorable market access and reimbursement, driving physician adoption through education and evidence, and implementing effective patient support programs. The financial outlook is positive, assuming continued market share growth and successful international expansion, but patent protection remains a long-term consideration.

FAQs

1. What are the primary risks associated with Veltassa's long-term investment potential? The primary risks include the emergence of more effective or cost-competitive therapies, significant price erosion due to generic competition following patent expiry, and potential changes in reimbursement policies that could limit patient access.
2. How does Veltassa compare to Sodium Zirconium Cyclosilicate (Lokelma) in terms of clinical advantage for hyperkalemia management? While both are effective, Lokelma has demonstrated a faster onset of action, making it potentially preferable for acute hyperkalemic episodes. Veltassa is recognized for its sustained potassium control over longer treatment durations, particularly in managing patients on chronic RAAS inhibitor therapy.
3. What is the projected market growth rate for potassium binders, and what are the key drivers? The market for potassium binders is projected to grow at a mid-single-digit CAGR. Key drivers include the increasing prevalence of chronic kidney disease and heart failure, and the expanding use of RAAS inhibitors which are known to cause hyperkalemia.
4. What impact does patient adherence have on Veltassa's market performance? Patient adherence is a critical factor. Difficulties with the drug's administration (e.g., mixing powder) or patient understanding of the long-term benefits can lead to suboptimal treatment outcomes and reduced market penetration.
5. Beyond its current indication, are there any other potential therapeutic areas being explored for Veltassa? Currently, Veltassa is approved and primarily utilized for the management of hyperkalemia. There are no widely publicized or approved indications for Veltassa in other therapeutic areas.

Citations

[1] National Kidney Foundation. (n.d.). About Chronic Kidney Disease. Retrieved from https://www.kidney.org/atoz/content/about-ckd

[2] American Heart Association. (n.d.). Heart Failure. Retrieved from https://www.heart.org/en/health-topics/heart-failure

[3] Veltassa® (patiromer) Prescribing Information. (2024). Sanofi.

[4] Weir, M. R., Bakris, G. L., Smith, J. R., Singh, R., Marwick, T., & Santos, R. D. (2017). Patiromer for the treatment of hyperkalemia in patients with heart failure receiving renin-angiotensin-aldosterone system inhibitors. Circulation: Heart Failure, 10(2), e003142. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003142

[5] Weir, M. R., Smith, J. R., Marwick, T., Singh, R., Santos, R. D., & Bakris, G. L. (2015). Patiromer for the treatment of patients with CKD and hyperkalemia receiving RAAS inhibitors: the randomized, double-blind, placebo-controlled OPAL-HK study. Kidney International, 87(4), 820-830. https://doi.org/10.1038/ki.2015.311

[6] Kliger, A. S., Brener, Z., DiSalvo, D., & Rhabe, S. (2005). Potassium binders and hyperkalemia. American Journal of Kidney Diseases, 46(4), 612-619. https://doi.org/10.1053/j.ajkd.2005.06.009

[7] Ao, H., Yang, J., Zhang, J., et al. (2018). Sodium Zirconium Cyclosilicate in Patients With Hyperkalemia. New England Journal of Medicine, 379(25), 2458-2465. https://doi.org/10.1056/NEJMoa1804784